Voluntary Recall Announced for One Lot of Cidofovir Injection (Vistide) Solution

“Gilead Sciences, Inc. is voluntarily recalling lot B120217A of Vistide® (cidofovir injection) to the user level due to the presence of  particulate matter found in some vials of this lot. Gilead is not currently aware of any complaint attributable to the particles. … “Vistide is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). … “Gilead has notified its distributors and customers by e-mail and recall letter and is arranging for return of all recalled product. Before injecting Vistide, healthcare providers should inspect the product and any product with lot number B120217A should not be injected. “Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using Vistide.” More information is available: FDA: Safety alert